A Novel Candidate Compound with Urethane Structure for Anticancer Drug Development

By  

Current Drug Discovery Technologies, Vol. 4, Iss. 2, 2007-08 ,pp. : 69-76

Bentham Science Publishers

Access to resources Recommend Favorite

Preventability of Drug-Related Harms - Part II: Proposed Criteria, Based on Frameworks that Classify Adverse Drug Reactions

By Aronson Jeffrey K.   Ferner Robin E.  

Drug Safety, Vol. 33, Iss. 11, 2010-11 ,pp. : 995-1002

Adis International

Access to resources Recommend Favorite

Clinical Risk Management in Dutch Community Pharmacies: The Case of Drug-Drug Interactions

By Buurma Henk   De Smet Peter A.G.M   Egberts Antoine C.G.  

Drug Safety, Vol. 29, Iss. 8, 2006-01 ,pp. : 723-732

Adis International

Access to resources Recommend Favorite

Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice

By Farkas Attila S.   Nattel Stanley  

Drugs, Vol. 70, Iss. 5, 2010-03 ,pp. : 573-603

Adis International

Access to resources Recommend Favorite

A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

By Guo Jeff J.   Pandey Swapnil   Doyle John   Bian Boyang   Lis Yvonne   Raisch Dennis W.  

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 657-666

Blackwell Publishing

Access to resources Recommend Favorite